Moderna’s expected revenue fell short in 2023 by nearly $7 billion but, even they only brought in $6.7 billion, they still consider it a success as it actually met their forecast for the year.

The company had more than $18 billion in sales in 2022; the shot was their only commercially available product. Company officials blamed 2023’s two-thirds drop on dwindling COVID cases and public concerns for getting vaccinated.

“Moderna said it expects to return to sales growth in 2025 with the launch of new products,” CNBC said. “The company currently has 45 products in development, nine of which are in late-stage trials. They include Moderna’s combination shot targeting Covid and the flu, which could win approval as early as 2025.”

SOURCE:

CNBC January 8, 2024